Syndax Pharmaceuticals (SNDX) Shares Outstanding (Weighted Average) (2015 - 2026)

Syndax Pharmaceuticals' Shares Outstanding (Weighted Average) history runs 12 years deep, the most recent figure standing at $88.3 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 2.42% year-over-year to $88.3 million; the TTM figure through Mar 2026 stood at $88.3 million (up 2.42% YoY), while the FY2025 annual figure was $86.6 million, up 1.17% from the prior year.
• Shares Outstanding (Weighted Average) was $88.3 million for Q1 2026 at Syndax Pharmaceuticals, up from $86.6 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $88.3 million in Q1 2026 to a low of $59.0 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $76.1 million across 5 years, with a median of $85.2 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Weighted Average) rose 22.72% in 2024, then increased 1.13% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $60.8 million in 2022, then rose by 15.82% to $70.4 million in 2023, then climbed by 21.67% to $85.6 million in 2024, then gained by 1.17% to $86.6 million in 2025, then climbed by 1.88% to $88.3 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $88.3 million (Q1 2026), $86.6 million (Q4 2025), and $86.6 million (Q3 2025), per Business Quant data.